Clinical trial
Prognosis of SARS-Cov 2 Positive Patients Receiving Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Antagonists (ARBs)
NCT04357535 is registered in ClinicalTrials.gov with Hakeam Abdulaziz Hakeam as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prognosis of SARS-Cov 2 Positive Patients Receiving Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Antagonists (ARBs)
- Lead sponsor
- Hakeam Abdulaziz Hakeam
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 10, 2020
- Completion date
- August 1, 2020
- Enrollment
- 314 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.